Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements

Moniek Root, Clemens Löwik, L Mezzanotte*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)


Targeting nanomedicine to brain tumors is hampered by the heterogeneity of brain tumors and the blood brain barrier. These represent the main reasons of unsuccessful treatments. Nanomedicine based approaches hold promise for improved brain tissue distribution of drugs and delivery of combination therapies. In this review, we describe the recent advancements and latest achievements in the use of nanocarriers, virus and cell-derived nanoparticles for targeted therapy of brain tumors. We provide successful examples of nanomedicine based approaches for direct targeting of receptors expressed in brain tumor cells or modulation of pathways involved in cell survival as well as approaches for indirect targeting of cells in the tumor stroma and immunotherapies. Although the field is at its infancy, clinical trials involving nanomedicine based approaches for brain tumors are ongoing and many others will start in the near future.

Original languageEnglish
Pages (from-to)1803-1812
Number of pages10
JournalCurrent Pharmaceutical Design
Issue number13
Publication statusPublished - 2017

Bibliographical note

Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Research programs

  • EMC NIHES-03-30-02


Dive into the research topics of 'Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements'. Together they form a unique fingerprint.

Cite this